Gefitinib is a first-generation targeted drug for the treatment of lung adenocarcinoma, which blocks conduction by inhibiting EGFR's autophosphorylation and inhibits the proliferation of tumor cells. This evidence concerns the gene EGFR and lung adenocarcinoma.